Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent. The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India. Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
相关推荐
Celebrity billionaire loses $430 mn as Netflix valuation erases an entire State Bank of India in m-cap
Ex-Chhattisgarh CM Bhupesh Baghel’s father passes away
Buy these 4 stocks for gains, charts show strength; Sensex, Nifty fall below support levels
Centre slashes windfall tax for domestic crude oil to zero; no duty on export of diesel, petrol, ATF
Bank of Baroda raises Rs 1,000 cr via housing bonds
China Covid scare keeps markets on tenterhooks
- 最近发表
- Windfall tax cut on oil, fuels; check duty cuts on diesel, petrol, ATF exports, local crude
- ATF price hiked by steep 8
- YouTube introduces BrandConnect and Podcasts for creators in India
- Equity investors poorer by Rs 4
- Will Nifty reclaim 19500 or fall further in trade - See GIFT Nifty, FII data, F&O ban, crude, more before market opens
- Axis Bank Rating- Buy - Committed to compete with banks
- WPP is said to weigh options for 40% stake in Bain’s Kantar
- Cholamandalam Investment and Finance reports standalone Q4 profit at Rs 852
- YashoBhoomi Convention Centre- A look inside world’s finest state-of-the-art facilities – See Pics
- Eat on time- Documents after study links between meal timings and cardiovascular disease risk
- 随机阅读
- Bank of Baroda, Axis Bank among 131 BSE stocks to hit 52-week highs, 10 fall to 52-week lows
- Bajaj Finance Rating- SELL Sailing through good times
- AU Small Finance Bank set to maintain its industry-leading loan growth
- Asian stocks boosted by Japan as investors mull next Fed rate hike; treasuries mixed, Bitcoin and gold waver
- Elon Musk’s astounding surge in wealth- From $24 billion to $219 billion in just two years
- Buy these two stocks for gains; Nifty resistance at 17800–17850, Bank Nifty likely to outperform
- Ayodhya gears up for Ram Temple inauguration! Uttar Pradesh govt to start helicopter services for devotees, increase railway capacity and more
- Exchanges standardise compliance by listed entities
- BankBazaar
- Axis Bank, Adani Enterprises among 118 BSE stocks to hit 52-week highs, 31 BSE stocks fall to 52-week lows
- China stocks struggle on weak sentiment after state fund’s support
- Embarking on a new era- India’s exciting space journey in 2024 with FDI and Space Activity Bill
- Buy these two stocks for gains in near term as Nifty 50 may head to resistance level of 17800 in coming days
- Buy these two stocks with strong technical setup; Nifty uptrend intact despite consolidation
- Buy these two stocks for near-term gains while Nifty edges towards 17600-17700
- Buy these two stocks for gains while Nifty’s short-term trend remains choppy
- Chai pe Charcha with BrandWagon_1
- BankBazaar IPO planned in next 12-18 months; FY23 net revenue at Rs 160 crore
- Equity MFs see Rs 15,498-crore inflow in June amid volatile stock market
- Bank Nifty Highlights- Nifty Bank F&O expiry shifts to Friday; index ends above 44150, Kotak Bank gains, Federal Bank falls
- 搜索
- 友情链接